Press Release

March 12, 2020

Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint

SUMMIT, N.J., March 12, 2020 — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic […]
December 5, 2019

Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode […]
November 12, 2019

Engage Therapeutics to Present at the Stifel 2019 Healthcare Conference

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode […]
September 9, 2019

Engage Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

SUMMIT, N.J., Sept. 9, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in patients […]